Carla Bartosch

ORCID: 0000-0003-0646-7667
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • Endometrial and Cervical Cancer Treatments
  • Gestational Trophoblastic Disease Studies
  • Preterm Birth and Chorioamnionitis
  • Uterine Myomas and Treatments
  • PARP inhibition in cancer therapy
  • BRCA gene mutations in cancer
  • Cancer-related molecular mechanisms research
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer
  • Prenatal Screening and Diagnostics
  • Cervical Cancer and HPV Research
  • Ectopic Pregnancy Diagnosis and Management
  • CRISPR and Genetic Engineering
  • Epigenetics and DNA Methylation
  • Pregnancy-related medical research
  • Cardiovascular Disease and Adiposity
  • Cardiovascular, Neuropeptides, and Oxidative Stress Research
  • Medical Imaging and Pathology Studies
  • Ocular Oncology and Treatments
  • Maternal and Perinatal Health Interventions
  • Testicular diseases and treatments
  • Maternal and fetal healthcare
  • Reproductive System and Pregnancy
  • Circular RNAs in diseases

Instituto Português de Oncologia Francisco Gentil
2015-2025

IPO Porto
2015-2025

Hospital de São João
2009-2025

Universidade do Porto
2011-2022

Hospital Pedro Hispano
2022

Institute of Biomedical Science
2015-2017

Anna Needs Neuroblastoma Answers
2017

Centro Hospitalar do Porto
2014-2015

Instituto Português de Oncologia de Coimbra Francisco Gentil
2015

// Carla Bartosch 1,2,3 , Sara Monteiro-Reis 1,2 Diogo Almeida-Rios Renata Vieira 1 Armando Castro 4 Manuel Moutinho Marta Rodrigues Inês Graça 2 José Lopes 3,4,5,* and Carmen Jerónimo 2,6,* Department of Pathology, Portuguese Oncology Institute-Porto (IPO-Porto), Porto, Portugal Cancer Epigenetics & Biology Group, Research Center, Institute-Porto, 3 Pathology Oncology, Medical Faculty, University Centro Hospitalar São João (CHSJ), 5 IPATIMUP...

10.18632/oncotarget.6691 article EN Oncotarget 2015-12-19

Lymphovascular space invasion (LVSI) in endometrial cancer (EC) is an important prognostic variable impacting on a patient's individual recurrence risk and adjuvant treatment recommendations. Recent work has shown that grading the extent of LVSI further improves its strength patients with stage I endometrioid EC. Despite this, there little information reproducibility assessment Therefore, we designed study to evaluate interobserver agreement discriminating true from mimics (Phase I)...

10.1111/his.13871 article EN cc-by Histopathology 2019-06-03

Abstract Peritoneal dissemination is a particular form of metastasis typically observed in ovarian cancer and the major cause for poor patient’s outcome. Identification molecular players involved can offer an approach to develop treatment strategies improve clinical prognosis. Here, we identified mesothelin (MSLN) as crucial protein multistep process peritoneal cancer. We demonstrated that MSLN overexpressed primary matched high-grade serous carcinomas (HGSC). Using several genetically...

10.1038/s41389-020-00246-2 article EN cc-by Oncogenesis 2020-07-01

Patients with endometrial endometrioid carcinoma (EEC) that present advanced primary disease and develop recurrences have a poor outcome. The phenotype of EEC metastases is poorly studied. We evaluated the morphological features ER-alpha/PRA/p53 immunohistochemical expression sample 45 compared to matched tumors. Additionally, we studied methylation levels ER-alpha/PRA gene promoters. distribution histological FIGO grade was significantly different in metastases, which disclosed higher than...

10.1371/journal.pone.0134969 article EN cc-by PLoS ONE 2015-08-07

Endometrial carcinoma (EC) is the most common gynecologic malignancy in developed countries and fourth frequent women worldwide. The cornerstone of treatment for EC surgery. Clinicopathological features are currently used to help determine individual risk recurrence need adjuvant after Nonetheless, there significant interobserver variability assigning histologic subtype when using a morphological classification, revealing more unified approach. Cancer Genome Atlas (TCGA) project identified 4...

10.2196/34461 article EN cc-by JMIR Research Protocols 2022-05-27

Primary heart neoplasms are rare occurring with an estimated incidence of 0.0017-0.19%. Myxoma is the most prevalent primary tumor. The right atrium unusual localization, only in 15-20% myxoma cases. We report a case massive atrial causing tricuspid valve obstruction and presenting as syncope exertional dyspnea. This illustrates influence myxoma's size, position mobility well patient's body posture respiration to development signs symptoms. Three-dimensional echocardiography proved useful...

10.1186/1476-7120-8-23 article EN cc-by Cardiovascular Ultrasound 2010-06-18

Women with Lynch syndrome (LS) have a high risk of developing endometrial carcinoma (EC) and, less frequently, ovarian carcinoma. As EC not uncommonly is the first malignancy, prophylactic hysterectomy (PH) has been increasingly implemented. In this study, we report clinicopathologic features series 70 LS patients who underwent either PH (n=39) or nonprophylactic (NPH) (n=31) at 3 tertiary referral centers. Among 39 PH, 2 had tumors seen grossly, whereas 37 showed no macroscopic lesions....

10.1097/pas.0000000000000684 article EN The American Journal of Surgical Pathology 2016-06-24

Endometrial stromal sarcomas (ESSs) are rare tumors whose classification is still controversial. In this study, the authors studied 19 patients diagnosed with ESS at Hospital S João, Porto, Portugal; reviewed their files and material; performed immunohistochemical study for CD10, desmin, smooth muscle actin markers, aiming to compare low-grade endometrial (LG-ESSs) undifferentiated (UESs) using World Health Organization (WHO) classification. Twelve cases (63%) were classified as LG-ESS 7...

10.1177/1066896909337600 article EN International Journal of Surgical Pathology 2009-05-29

Deleterious variants in the BRCA1/BRCA2 genes and homologous recombination deficiency (HRD) status are considered strong predictors of response to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi). The introduction PARPi clinical practice for treatment patients with advanced ovarian cancer imposed changes molecular diagnosis variants. tumor testing by next-generation sequencing (NGS) can detect simultaneously both somatic germline variants, allowing identification more higher likelihood...

10.3389/fonc.2020.01318 article EN cc-by Frontiers in Oncology 2020-07-31

BRCA1 and BRCA2 mutations are responsible for hereditary breast ovarian cancer, but they also confer an increased risk the development of rarer cancers associated with this syndrome, namely, cancer pancreas, male breast, peritoneum, fallopian tube. The objective work was to quantify contribution founder c.156_157insAlu c.3331_3334del etiology in unselected hospital-based cohorts Portuguese patients diagnosed these cancers, by using a strategy that included testing archival tumor tissue. A...

10.1371/journal.pone.0161438 article EN cc-by PLoS ONE 2016-08-17
Coming Soon ...